Document is current
Any future updates will be listed below
-
Authors
Boland, Sebastian https://orcid.org/0000-0002-6694-2039
Swarup, Sharan
Ambaw, Yohannes A.
Malia, Pedro C. https://orcid.org/0000-0003-1234-8103
Richards, Ruth C.
Fischer, Alexander W.
Singh, Shubham
Aggarwal, Geetika
Spina, Salvatore
Nana, Alissa L. https://orcid.org/0000-0003-3474-8044
Grinberg, Lea T. https://orcid.org/0000-0002-6809-0618
Seeley, William W.
Surma, Michal A. https://orcid.org/0000-0001-7833-2214
Klose, Christian
Paulo, Joao A. https://orcid.org/0000-0002-4291-413X
Nguyen, Andrew D. https://orcid.org/0000-0002-9492-9472
Harper, J. Wade https://orcid.org/0000-0002-6944-7236
Walther, Tobias C. https://orcid.org/0000-0003-1442-1327
Farese, Robert V. Jr https://orcid.org/0000-0001-8103-2239
-
Funding
Funding for this research was provided by:
The Bluefield Project. Grant # not applicable.
- License Information
-
More Information
Article History
Received: 8 October 2021
Accepted: 21 September 2022
First Online: 7 October 2022
Competing interests
: J.W.H. is a founder and scientific advisory board member of Caraway Therapeutics Inc. and a founding scientific board member of Interline Therapeutics Inc. R.V.F. serves gratis on the board of the Bluefield Project to Cure FTD. T.C.W. is a founder and scientific advisory board chair of Antora Bio Inc. The remaining authors declare no competing interests.
